Epsilon M&A Deal Report - Check-Points
Transaction Multiples for the Valuation of Private Companies
Vimian Group / Check-Points
No EMAT :
116329
Announced Date :
23/08/2021
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Vimian Group
Target :
Check-Points
Country :
Netherlands
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
Business Description :
Founded in 2002, Check-Points is a molecular diagnostics company focusing on salmonella and antimicrobial resistance diagnostics. > Produces tests for two principal markets: food safety human...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
|
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 52
| Date | Acquirer | Target | Country | Multiples | See details |
| 03/07/2023 | Novacyt | Yourgene Health | United Kingdom | ** | 116303 |
| 08/03/2022 | Sourcebio International | LdPath (now Source LdPath) | United Kingdom | ** | 116280 |
Source: Epsilon Research / EMAT
